89 results
6-K
EX-99.1
BLU
Bellus Health Inc
2 Jun 23
Notice of Annual and Special Meeting of Shareholders
4:25pm
based on the following criteria:
the then current market value of the underlying Common Shares;
the “Black-Scholes” value of the stock options … , converted into US dollars at the average rate of the corresponding year.
Calculated as of the grant date using the Black-Scholes option pricing model
6-K
EX-99.1
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
option granted is estimated on the date of grant using the Black-Scholes pricing model. Expected volatility is estimated by considering historic
6-K
EX-99.2
BLU
Bellus Health Inc
30 Mar 23
Notice of Annual and Special Meeting of Shareholders
11:22am
Executive Officers based on the following criteria:
the then current market value of the underlying Common Shares;
the “Black-Scholes” value … , converted into US dollars at the average rate of the corresponding year.
Calculated as of the grant date using the Black-Scholes option pricing model
6-K
EX-99.1
BLU
Bellus Health Inc
29 Mar 23
Current report (foreign)
5:26pm
of grant and is expensed over the award’s vesting period with a corresponding increase to equity. The Company uses the Black Scholes model to calculate … and administrative expenses).
The fair value of each stock option granted is estimated on the date of grant using the Black-Scholes pricing model. Expected
6-K
EX-99.1
BLU
Bellus Health Inc
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
granted is estimated on the date of grant using the Black-Scholes pricing model. Expected volatility is estimated by considering historic average share
6-K
EX-99.1
l91 9eimeqz3wny4lo
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
6-K
EX-99.1
1m2e9bn1lrlvd
11 May 22
Condensed Consolidated Interim Financial Statements of
5:05pm
6-K
EX-99.2
3deg p9mfh4
7 Apr 22
Notice of Annual Meeting of Shareholders
9:01am
6-K
EX-99.1
x8drr550gpqorfcjs
5 Apr 22
Current report (foreign)
4:07pm
40-F
EX-99.2
8svsem1wl
23 Feb 22
Annual report (Canada)
5:20pm
6-K
EX-99.2
275n8sltjsa0po4mw
13 Dec 21
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
7:19am
6-K
EX-99.1
r2vbhvrzary gj90o
10 Nov 21
Condensed Consolidated Interim Financial Statements of
4:42pm
6-K
EX-99.1
6ylhbjx
11 Aug 21
Condensed Consolidated Interim Financial Statements of
4:43pm
6-K
EX-99.1
glassu g2wcwlndvmiq
10 May 21
Condensed Consolidated Interim Financial Statements of
4:48pm
6-K
EX-99.2
wultx
9 Apr 21
Notice of Annual Meeting of Shareholders
12:00am
6-K
EX-99.1
jhb 2h80m
8 Apr 21
Bellus HEALTH 2020 ANNUAL REPORT
10:16am
40-F
EX-99.2
ndaher4 erojo0p42zk
25 Feb 21
Annual report (Canada)
4:58pm
6-K
EX-99.1
nus1tz0wxh74kir94fh
12 Nov 20
Condensed Consolidated Interim Financial Statements of
4:09pm
6-K
EX-99.1
61j76ahxq96qg7g33r
13 Aug 20
Condensed Consolidated Interim Financial Statements of
4:01pm
6-K
EX-99.1
sxxgxn4v2ocymir3qlu
14 May 20
Condensed Consolidated Interim Financial Statements of
5:12pm